

Product Data Sheet

Product Name: BC-DXI-495

Cat. No.: GC79562

Chemical Properties

Cas. No. 2421117-94-2


Formula $C_{28}H_{30}N_4O_4S$ M.Wt 518.63

Solubility DMSO: 50 mg/mL (96.41 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

BC-DXI-495 is a AIMP2-DX2 inhibitor. BC-DXI-495 disrupts the interaction of HSP70 and destabilizes

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

DX2. BC-DXI-495 induces DX2 degradation via Siah1 -mediated ubiquitination. BC-DXI-495 exerts tumor suppressive activity in cancer cells. BC-DXI-495 serves as a chemical probe to elucidate the mechanism of action of arylsulfonamide-based DX2 inhibitors. BC-DXI-495 can be used in lung cancer research [1].

In Vitro, BC-DXI-495 (Compound 2) inhibits the level of NanoLuciferase-tagged DX2 by 67.10% [1]. BC-DXI-495 inhibits the degradation of DX2 protein, with an IC₅₀ value of 4.20 μ M [1]. BC-DXI-495 (72 h) inhibits the viability of A549 lung cancer cells with an EC₅₀ of 14.2 μ M [1].

References:

[1]. Sivaraman A, et al. Synthesis and Structure-Activity Relationships of Arylsulfonamides as AIMP2-DX2 Inhibitors for the Development of a Novel Anticancer Therapy. J Med Chem. 2020;63(10):5139-5158.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA